title: Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood.
abstract: Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has resulted in cases of inadvertent foetal exposure. Here, we used clinically relevant dosing to examine the effects of maternally administered sustained-release naltrexone on the rat brain by examining offspring at birth and in adulthood. Maternal treatment (naltrexone or placebo implant) started before conception and ceased during gestation, birth or weaning. Morphometry was assessed in offspring at birth and adulthood. Adult offspring were evaluated for differences in locomotor behaviour (basal and morphine-induced, 10 mg/kg, s.c.) and opioid neurochemistry, propensity to self-administer morphine and cue-induced drug-seeking after abstinence. Blood analysis confirmed offspring exposure to naltrexone during gestation, birth and weaning. Naltrexone exposure increased litter size and reduced offspring birth-weight but did not alter brain morphometry. Compared to placebo, basal motor activity of naltrexone-exposed adult offspring was lower, yet they showed enhanced development of psychomotor sensitization to morphine. Developmental naltrexone exposure was associated with resistance to morphine-induced down-regulation of striatal preproenkephalin mRNA expression in adulthood. Adult offspring also exhibited greater operant responding for morphine and, in addition, cue-induced drug-seeking was enhanced. Collectively, these data show pronounced effects of developmental naltrexone exposure, some of which persist into adulthood, highlighting the need for follow up of humans that were exposed to naltrexone in utero.
authors.affiliation: Experimental and Regenerative Neurosciences, School of Animal Biology, The University of Western Australia, Perth, Western Australia, Australia.
authors.forename: Waleed O
authors.initials: WO
authors.lastname: Farid
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Lawrence
authors.forename: Elena V
authors.initials: EV
authors.lastname: Krstew
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Tait
authors.forename: Gary K
authors.initials: GK
authors.lastname: Hulse
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Dunlop
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D003692:Delayed-Action Preparations / Q000493:pharmacokinetics / Q000633:toxicity; D004399:Dynorphins / Q000235:genetics / Q000378:metabolism; D004745:Enkephalins / Q000235:genetics / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D008297:Male; D009020:Morphine / Q000008:administration & dosage; D009043:Motor Activity / Q000187:drug effects; D009271:Naltrexone / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D009292:Narcotic Antagonists / Q000493:pharmacokinetics / Q000633:toxicity*; D009294:Narcotics / Q000008:administration & dosage; D017072:Neostriatum / Q000378:metabolism; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000235:genetics / Q000378:metabolism; D012646:Self Administration
chemical_list: D003692:Delayed-Action Preparations; D004745:Enkephalins; D009292:Narcotic Antagonists; D009294:Narcotics; D011498:Protein Precursors; D017450:Receptors, Opioid, mu; C036448:pre-prodynorphin; C010410:6 beta-hydroxynaltrexone; D009271:Naltrexone; D004399:Dynorphins; D009020:Morphine; C033660:preproenkephalin